Abstract: Mass spectrometry analysis of renal cancer cell lines recently suggested that the ProteinTyrosine Phosphatase Receptor Type J (PTPRJ), an important regulator of tyrosine kinase receptors, is tightly linked to the von-Hippel Lindau protein (pVHL). Therefore, we aimed to characterize the biological relevance of PTPRJ for clear cell renal cell carcinoma (ccRCC). In pVHL negative ccRCC cell lines both RNA and protein expression levels of PTPRJ were lower than those in the corresponding pVHL reconstituted cells. Quantitative RT-PCR and Western blot analysis of ccRCC with known VHL mutation status and normal matched tissues as well as RNA in situ hybridization on a Tissue Microarray (TMA) confirmed a decrease of PTPRJ expression in more than 80 % of ccRCCs, but in only 12 % of papillary RCCs. ccRCC patients with no or reduced PTPRJ mRNA expression had a less favourable outcome than those with a normal expression status (p = 0.05). Sequence analysis of 32 PTPRJ mRNA negative ccRCC samples showed five known polymorphisms, but no mutations implying other mechanisms leading to PTPRJ's down-regulation. Selective silencing of HIF-by siRNA and reporter gene assays demonstrated that pVHL inactivation reduces PTPRJ expression through a HIF-dependent mechanism, which is mainly driven by HIF-2 stabilization. Our results suggest PTPRJ as a member of a pVHL controlled pathway whose suppression by HIF is critical for ccRCC development. expression through a HIF-dependent mechanism, which is mainly driven by HIF-2 stabilization. Our results suggest PTPRJ as a member of a pVHL controlled pathway whose suppression by HIF is critical for ccRCC development.
INTRODUCTION
Most clear cell renal cell carcinomas (ccRCC) are characterized by a bi-allelic somatic inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene [1] . The VHL protein (pVHL) is an important regulator of the Hypoxia Inducible Factor-(HIF-), microtubule stabilization, maintenance of the primary cilium, mitotic regulation and cell mobility [2] . The loss of function of pVHL leads to HIF-stabilization and up-regulation of HIF target genes which are involved in cell growth and proliferation, angiogenesis, invasion and metastasis.
Examples of up-regulated HIF-target genes are VEGF-A, EPO, EGFR and CAIX [3] which represent also potential anticancer drug targets. Data about genes and proteins down-regulated due to pVHL functional deficiency are rare. Examples include important genes/proteins such as fibronectin [4] , E-cadherin [5] , PAX2 [6] and p53 [7] .
Recent mass spectrometry experiments with ccRCC cell lines [8] showed that the expression of the protein tyrosine phosphatase receptor type J (PTPRJ) is associated with the presence of pVHL. PTPRJ is composed of an extracellular domain that contains eight fibronectin type III repeats, a transmembrane domain, and a cytoplasmic end comprising a single catalytic domain [9] . In vitro, the receptor is involved in the regulation of cellular differentiation, proliferation, growth and migration [10] [11] [12] [13] [14] which supports its potential relevance for cancer development. In colon, lung and breast cancer PTPRJ is affected by allelic imbalances and missense mutations [15, 16] . Furthermore, several membraneassociated tyrosine kinase receptors are controlled by PTPRJ, among them there are established or potential molecular anti-cancer drug targets, e.g. EGFR [17] , PDGFR- [18] , VEGFR2 [19] and HGFR (also termed c-MET) [20] .
To date the molecular mechanisms leading to down-regulation of PTPRJ expression in ccRCC are unknown. Consequently, here we investigated the influence of the pVHL-HIF axis on PTPRJ expression in human ccRCC.
MATERIALS AND METHODS

Tissue specimens and tissue microarray
For quantitative RT-PCR analysis of PTPRJ mRNA levels, frozen tissue samples of 17 ccRCCs and matched non-tumorous tissue were used. The pathological parameters of the ccRCCs are presented together with the VHL mutations in Table S1 (supplementary data). A previously described tissue microarray (TMA) was used [21] to determine PTPRJ mRNA expression in ccRCCs, pRCC and normal kidney samples. This study was approved by the local commission of ethics (reference number StV. . All tissue specimens were supplied by the tissue biobank of the University Hospital Zurich.
mRNA quantification
Quantitative analysis of PTPRJ mRNA expression was performed by qRT-PCR using 17 ccRCCs with known VHL mutation status. Normal matched tissue was available for each tumour and used as control. Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) and quantified using the Nanodrop spectrometer. Total RNA (0.2 to 1 g) was reverse-transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). The expression of the mRNAs of PTPRJ, HIF-1 , HIF-2 , and GLUT-1 was quantified using the following TaqMan gene expression assays:
Hs00174561_m1 (PTPRJ), Hs00936376_m1 (HIF-1 ), Hs01026146_m1 (HIF-2 ), and Hs00197884_m1 (GLUT-1). The expression assays were designed by Applied Biosystems and analysed using the 7900 Fast Real-time PCR System (Applied Biosystems). The data were quantified with the comparative C t method for relative gene expression and normalised using PPIA (expression assay Hs99999904_m1) [22] .
RNA in situ hybridization (RISH)
PTPRJ mRNA expression was analysed on a TMA by non-radioactive in situ hybridisation adapted from a previously published protocol [23] . Briefly, total mRNA was extracted from 
Mutation analysis of PTPRJ and VHL
For the mutation analysis of PTPRJ genomic DNA was extracted from 32 formalin fixed and paraffin embedded ccRCCs which were also on the large TMA. Five normal matched tissues were included in the analysis. The mutation analysis of PTPRJ and VHL was performed as previously described [16, 24] . Mutations were confirmed with at least one separate PCR and sequence analysis.
Cell lines
The 
Western blotting and antibodies
Total cell lysates were prepared with RIPA buffer (Sigma-Aldrich Corp, Saint Louis, MO, USA) supplemented with protease inhibitors (Complete protease inhibitor cocktail, Roche, Basel, Switzerland). For cell and tissue fractioning a Nuclear Extraction Kit (Active Motif, Carlsbad, CA, USA) and the TissueLyser (Qiagen, Hilden, Germany) were used, respectively.
Western blot was done as described [6] . Primary antibodies used were anti-pVHL (diluted Table S2 (supplementary data).
AllStars Negative controls (Qiagen) was used as negative control. To study the effects of PTPRJ overexpression in RCC4 cells, the pQE-TriSystem-6 vector (Qiagen) containing the ORF of the PTPRJ gene (Entrez Gene: 5795, Ensembl: ENSG00000149177, UniProtKB: Q12913) was used. The pQE-TriSystem-6 served as control (empty vector). Cells were grown for 24 h in a 6-well format and then transiently transfected with the expression vector. Cells were harvested after 96 h to evaluate PTPRJ expression levels by qRT-PCR and Western blot.
Luciferase gene reporter assay
Luciferase gene expression assays were performed as previously described [6] . The nucleotides between -2682 and +515 were defined as the putative promoter region of PTPRJ (Chr. 11p11.2; 47,971,665:48,222,839, positive strand, NCBI) considering the A(TG) translation site as +1 reference. The promoter region was synthesized from GenScript (Piscataway, NJ, USA) and cloned into firefly luciferase reporter plasmid pGL4.10 (Promega, Madison, WI, USA). pGL4.10P2P vector containing wild type P2P hypoxia response elements (HREs) of the human PHD2 promoter were provided by Roland Wenger (University of Zurich, Switzerland) and was used as positive control as previously described [6, 25] . Luciferase activity was measured 24 h later after cell lysis using the Dual-Luciferase reporter assay system (Promega). Relative luciferase units were determined according to the manufacturer's instructions (Promega) to generate the ratio of the values obtained from siHIF-2 and siSc treatments.
MTT proliferation assay
RCC4 cells were grown in a 6-well format for 24 h and transfected with the expression or control vector. MTT proliferation assay (Cell Proliferation Kit I MTT, Roche) was performed according to the manufacturer's protocol. Briefly, transfected cells were plated in a 96-well plate. After the incubation period, 10 l of the MTT labelling reagent (final concentration 0.5 mg/ml) was added to each well and cells were incubated for 4 h. Subsequently, 100 l of the solubilisation solution was added to the wells and cells were incubated overnight at 37°C. The solubilized formazan product was quantified using an ELISA reader (Tecan, Infinite f200) at wavelength 570 nm. The analysis of cell proliferation was performed after 96 h, 120 h, 144 h and 168 h.
Statistical analysis
Analysis between groups was done with 2-way ANOVA and post-hoc Bonferroni multiple comparison (GraphPad Prism 5) . Contingency table analysis and Pearson's Chi-squared tests were calculated using SPSS 17.0 statistical software package. Survival curves were estimated with the Kaplan-Meier method and the log rank test. P values < 0.05 were considered statistically significant.
RESULTS
Direct correlation of PTPRJ and pVHL expression in RCC cell lines
Previous mass spectrometry experiments performed with pVHL-deficient and pVHL-reexpressing RCC cell lines identified PTPRJ positively linked to pVHL expression [8] . To confirm that PTPRJ is influenced by the VHL/HIF axis we used the pVHL-deficient renal cancer cell lines 786-O and RCC4 and their corresponding stable pVHL transfectants.
Compared to the correspondent pVHL-negative cell lines both PTPRJ mRNA (Fig. 1A ) and protein levels (Fig. 1B and 1C) were increased in the presence of pVHL.
PTPRJ mRNA expression is decreased in ccRCC tissue
To quantitatively evaluate PTPRJ mRNA expression in human RCC samples we performed qRT-PCR with 17 ccRCCs and normal matched tissues. PTPRJ expression was reduced in 15 of 17 ccRCCs (88 %) (Fig. 1D ) when compared to normal renal tissues. A strong PTPRJ expression was seen in one VHL wild type tumour and in one ccRCC with a missense mutation that causes an amino acid exchange at codon 88 (Fig. 1D, Table S1 ). Western blot analysis with three matched normal/tumour pairs demonstrated a direct correlation between mRNA and protein expression of PTPRJ (Fig. 1E) .
As commercially available PTPRJ antibodies were not specific in formalin fixed and paraffin embedded tissues, the expression of PTPRJ was analysed by RNA in situ hybridization (RISH). The specificity of DIG-labelled RNA probes for PTPRJ was confirmed by Northern Blot analysis using total RNA from HeLa cells (positive control). The antisense probes bound a 7.8 kb band corresponding to the PTPRJ transcript (data not shown).
PTPRJ RISH analysis on a TMA showed strong positivity in the proximal tubular cells of all analysed normal kidney tissue samples (Fig. 2) , whereas in 198 of 232 (85 %) analysable ccRCCs, but in only 5 of 41 (12 %) of pRCCs PTPRJ expression was reduced (p < 0.001). ccRCC patients with no or low PTPRJ mRNA expression showed a worse prognosis than those with a normal expression status (p=0.05) (Fig. 3) . No associations were seen between PTPRJ expression and tumour stage and grade. The highly significant difference between the survival curves of patients with organ-confined and locally advanced tumours confirmed the validity of the clinical data (Fig S2) .
Mutation analysis of PTPRJ in ccRCC
Twenty-two PTPRJ negative and 10 weakly expressing ccRCC samples included in the TMA were selected for mutation analysis of exons 5, 6, 7 and 13 of PTPRJ. So far, all cancer-related amino-acid substitutions were identified in these four exons which code the extracellular portion responsible for interactions with ligands or other proteins [16] . Five normal matched tissues were also included in this analysis. We found two conservative (E206E and T233T) and three non-conservative (Q276P, R326Q and E872D) polymorphisms which were previously reported (UniprotKB/Swiss-Prot, Q12913 (PTPRJ_HUMAN)). There were no mutations affecting the reading frame of PTPRJ.
PTPRJ expression is HIF-2 -dependent
To determine the influence of the pVHL-HIF axis on PTPRJ expression we used different pVHL expressing and non-expressing RCC cell lines. In RCC4 cells expressing the pVHL mutant Y98N, which fail to degrade HIF- [26] , PTPRJ mRNA expression was comparable to pVHL-deficient RCC4. In contrast, RCC4 cells expressing the pVHL mutant Y98H, which has only a slight defect in ubiquitination of HIF- [26] , the PTPRJ mRNA level was increased and similar to the RCC4 VHL cell line (Fig. 4A ). An opposite effect was observed with GLUT1 mRNA whose expression increased in the presence of HIF- (Fig. 4B) .
Next, we silenced HIF-1 and HIF-2 by siRNA in the pVHL-deficient RCC4 cell line to determine whether the two HIF-isoforms were able to down-regulate PTPRJ mRNA expression. Efficient knock down of HIF-1 and HIF-2 was confirmed by qRT-PCR and Western blot analysis (Fig. 4C-G) . In RCC4, silencing of HIF-1 had positive effects on PTPRJ mRNA expression after 48 h (Fig. 5A) . In contrast, silencing of HIF-2 produced an increase of PTPRJ mRNA expression already after 24 h and reached a 2-fold up-regulation after 48 h (Fig. 5B) . We also silenced HIF-2 by siRNA in the pVHL and HIF-1 -null 786-O cell line. After 48 h we obtained an increase of PTPRJ mRNA expression which was comparable to that observed in 786-O VHL (Fig. 5D) . Efficient knock down of HIF-2 was confirmed by analysing the level of GLUT-1 mRNA (Fig. 5F ). Western blot analysis confirmed a strong increase of PTPRJ protein expression in both HIF-2 silenced ccRCC cell lines ( Fig. 5C and E) . Similar results were obtained with two additional HIF-2 siRNAs excluding possible off target effects (Fig. S1 A-C) .
HIF response elements in the promoter region influence PTPRJ expression
The putative promoter region of PTPRJ contains five HREs and three reverse HREs (Table   S3 , Fig. 6A ). To study the influence of the HREs on PTPRJ expression a luciferase reporter plasmid pGL4.10 construct containing 3.2kb of the PTPRJ promoter was generated (Fig. 6A) .
By silencing HIF-2 in 786-O cells (Fig. 6B ) the reporter activity of the vector increased significantly compared to those of the empty plasmid and the P2P promoter construct (Fig.   6C ). These results show that HIF-2 negatively regulates PTPRJ via the identified putative HREs in its promoter region.
PTPRJ regulates cell proliferation
RCC4 cells transfected with Qiagen expression vector pQE-TriSystem 6 containing the
PTPRJ gene showed increased mRNA and protein expression of PTPRJ (Fig. 6D and 6E ).
RCC4 cells transfected with the PTPRJ vector showed a significant reduced proliferation rate compared to the control group (Fig. 6F) .
We also silenced PTPRJ by siRNA in wild type pVHL expressing HK2 to see if PTPRJ down regulation leads to increased cell proliferation in the presence of pVHL.
Reduced expression negatively influenced cell proliferation after 72 h (Fig. S3A-B) and suggests that loss of PTPRJ is biologically relevant to promote growth of ccRCC, independently from the pVHL expression status.
DISCUSSION
We have demonstrated that decreased PTPRJ expression is characteristic for the vast majority of ccRCC. In vitro experiments showed that higher PTPRJ mRNA and protein expression levels are closely linked to the presence of functional pVHL. Down-regulation of PTPRJ is mainly dependent on HIF-2 stabilisation following pVHL loss.
Our TMA analysis showed no or low PTPRJ mRNA expression in 85 % of ccRCCs, whereas in most of the pRCCs PTPRJ mRNA levels were comparable to those in normal tissues. The fact that VHL is mutationally affected in about 70-80 % of ccRCCs [1, 27, 28] , suggests a close relationship between PTPRJ mRNA expression and pVHL functional integrity. This is supported by the observation that PTPRJ expression was normal in almost 90 % of the analysed pRCC in which VHL is hardly mutated [29] . This result confirms our recent proteomics finding of a relationship between PTPRJ expression and pVHL in human tissue [8] . In our test set of 17 ccRCC reduced PTPRJ mRNA expression was also seen in two of four tumours with wild type VHL. Other mechanisms of VHL inactivation, such as tumour hypoxia or hypermethylation of the VHL promoter, which occurs in about half of VHL wild type ccRCC [1, 28, 30] , may explain this observation.
Here, we identified PTPRJ as potential target of HIF-2 . HIF-1 and HIF-2 share high similarity in their DNA binding and dimerization domains, but they differ in their transactivation domains [31] . As a consequence, there are common gene targets, but also genes that are preferentially regulated by one of the two isoforms. HIF-1 seems to preferentially drive the transcription of genes encoding glycolytic enzymes and pro-apoptotic factors, such as BCL2/adenovirus E1B-interacting protein 1, NIP3 (BNIP3). In contrast, HIF-2 induces the expression of pro-survival factors such as VEGF, TGF-, and CCND1 [32] .
Studies demonstrated that HIF-can also down-regulate genes either by inducing repressors of transcription and by directly binding to hypoxia response elements (HREs) or to reverse HREs. The latter are present in the antisense strand of the promoter of HIF target genes.
Examples of genes directly down-regulated by HIF-1 are -fetoprotein [33] , PPAR- [34] and RECK [35] , whereas genes directly or indirectly down-regulated by HIF-2 have not been described to date.
The analysis of the putative PTPRJ promoter showed the presence of five putative HREs and three putative reverse HREs. Since we observed PTPRJ down-regulation in the presence of HIF-2 , we asked whether HIF could directly act as suppressor of PTPRJ transcription. Using 786-O cells, significant effects were seen with our luciferase gene reporter assays suggesting that the HREs and reverse HREs identified in the putative PTPRJ promoter region are important for suppressing PTPRJ expression by HIF-2 . It is of note that only a two-fold overexpression of PTPRJ in RCC4 cells was sufficient to produce a significant inhibitory effect on cell proliferation. Our result expands the findings of previous studies that describe anti-proliferative properties of PTPRJ in non-RCC tumour cell lines [10, 12, 14] .
To evaluate the presence of mutations of the PTPRJ gene, we performed a sequence analysis of the exons 5, 6, 7 and 13 of PTPRJ in 32 ccRCCs. We found two conservative and three non-conservative polymorphisms, but no mutation predicting severe consequences on PTPRJ function. Similar frequencies of these polymorphisms were found in studies which analysed the PTPRJ genotype in other tumour types and in other populations [36] [37] [38] . The real influence of these polymorphisms on PTPRJ expression and function is still not fully understood. Our results suggest that in ccRCC the down-regulation of PTPRJ expression is obviously not caused by mutations but mainly due to the deregulation of the pVHL/HIF pathway (Fig. 7 ).
PTPRJ's inhibitory effect on cell proliferation in ccRCC, as shown by us, and in other tumour types [14, 39 , 40 ] as well as its ability to regulate EGFR phosphorylation [17] suggest its important influence on the activity of EGFR. Although EGFR over-expression occurs in the majority of ccRCC and is correlated with rapid tumour cell proliferation and worse patient outcome [41, 42] , anti-EGFR targeted therapies have shown only low response rates [43, 44] . As demonstrated in non-small cell lung cancer, the success of such therapies is obviously dependent on EGFR activating mutations [45] which have not been found in ccRCC [41] . Antibodies against phosphorylated and activated EGFR are available but their use for reliably determining its tyrosine kinase activity status on formalin fixed, paraffin embedded tissue in routine diagnostics is challenging [46] . Despite the low number of tumors 
